In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 41 for your search:
Drug:  brentuximab vedotin
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25006, 2012-004128-39, U1111-1154-9784, NCT01909934

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25007, 2013-000232-10, U1111-1154-2250, NCT01990534

3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25001, 2010-024215-14, NCT01578499

4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25003, 2011-005450-60, NCT01712490

5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-014, NCT01777152

6.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25002, 2011-001240-29, NCT01492088

7.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 75
Sponsor: NCI, Other
Protocol IDs: 2560.00, NCI-2012-00924, P30CA015704, P01CA018029, NCT01620229

8.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AAAJ5050, NCT01657331

9.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00046, AMC-085, U01CA121947, NCT01771107

10.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 to 30
Sponsor: NCI
Protocol IDs: NCI-2013-00107, COG-AHOD1221, AHOD1221, U01CA097452, NCT01780662

11.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037

12.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-016, NCT01874054

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 17413, NCT01994850

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0706, NCT02096042

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 45 and under
Sponsor: Other
Protocol IDs: NYMC 564, NCT02098512

16.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0914, NCT01352520

17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: 11051, NCI-2011-01135, NCT01393717

18.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-012, NCT01421667

19.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-013, NCT01461538

20.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: NU 11H01, NCI-2011-00684, STU00046908, NCT01476410

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 72
Sponsor: Other
Protocol IDs: 11-142, NCT01508312

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-462, NCT01534078

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: Targeted BEACOPP, NCT01569204

24.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-015, NCT01716806

25.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FM-12-GCT01, 2012-004508-36, NCT01851200
1   
New Search